MKGAF (Merck KGaA) Cyclically Adjusted PS Ratio: (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MKGAF Merck KGaA MKGAF
87 GF Score
Price $151.92
GF Value $161.93
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Merck KGaA Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Merck KGaA  (OTCPK:MKGAF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Merck KGaA Cyclically Adjusted PS Ratio Related Terms


Merck KGaA Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Cyclically Adjusted PS Ratio Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.24 4.18 3.26 2.94 2.75

Merck KGaA Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.47 2.43 2.73 2.22 3.07

MKGAF vs ZTS, UTHR, VTRS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck KGaA Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck KGaA's Cyclically Adjusted PS Ratio falls into.


MKGAF
87GF Score
Merck KGaA MKGAF
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Merck KGaA's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Merck KGaA's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.532/131.3638*131.3638
=14.532

Current CPI (Jun. 2026) = 131.3638.

Merck KGaA Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 9.559 101.017 12.431
201612 9.499 101.217 12.328
201703 9.465 101.417 12.260
201706 9.352 102.117 12.030
201709 9.494 102.717 12.142
201712 9.879 102.617 12.646
201803 9.854 102.917 12.578
201806 10.178 104.017 12.854
201809 10.029 104.718 12.581
201812 10.202 104.217 12.859
201903 9.783 104.217 12.331
201906 10.263 105.718 12.753
201909 10.367 106.018 12.845
201912 11.156 105.818 13.849
202003 11.073 105.718 13.759
202006 10.433 106.618 12.855
202009 11.947 105.818 14.831
202012 12.608 105.518 15.696
202103 12.829 107.518 15.674
202106 13.493 108.486 16.338
202109 13.483 109.435 16.185
202112 13.705 110.384 16.310
202203 13.412 113.968 15.459
202206 13.648 115.760 15.488
202209 13.451 118.818 14.871
202212 13.271 119.345 14.607
202303 13.062 122.402 14.018
202306 13.272 123.140 14.158
202309 12.944 124.195 13.691
202312 12.921 123.773 13.713
202403 12.781 125.038 13.428
202406 13.253 125.882 13.830
202409 13.306 126.198 13.851
202412 13.293 127.041 13.745
202503 12.781 127.779 13.140
202506 13.700 128.412 14.015
202509 14.294 129.255 14.527
202512 14.052 129.361 14.270
202603 13.815 131.258 13.826
202606 14.532 131.364 14.532

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Merck KGaA (MKGAF) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of $151.92 is trading 6.2% below its estimated GF Value™ of $161.93. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for MKGAF:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $161.93 vs. price of $151.92 (6.2% below fair value)
  • GF Score™: 87/100 with 10 warning signs

No single metric tells the full story. See the MKGAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
87GF Score

Get the complete analysis for MKGAF

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$151.92
Price
$161.93
GF Value